Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer.

Abstract

A total of 40 previously treated patients with symptomatic advanced non-small-cell lung cancer (NSCLC) were subjected to second-line chemotherapy with mitomycin C plus vindesine (MV) or cisplatin plus epirubicin (PE). The 12 patients treated with the MV regimen showed no objective response (OR) or symptom palliation. In the 28 patients who received the PE regimen, we obtained a 25% partial response rate, with amelioration of tumor-related symptoms occurring in 35.7% of cases and improvement in the performance status being noted in 25% of subjects. Both regimens were well tolerated. These data show that the administration of cisplatin-based second-line chemotherapy to patients with symptomatic advanced NSCLC may be useful.

• Authors: C Gridelli, G Airoma, P Incoronato, R Pepe, G Palazzolo, A Rossi, A R Bianco
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 30 Issue 3 Pg. 212-4 ( 1992) ISSN: 0344-5704 [Print] Germany
• PMID: 1321007 (Publication Type: Journal Article)

Chemical References

• Epirubicin
• Mitomycin
• Cisplatin
• Vindesine

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Cisplatin (administration & dosage)
• Epirubicin (administration & dosage)
• Female
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Mitomycin (administration & dosage)
• Vindesine (administration & dosage)